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Objective: The objective of this study was to characterize patients with extracranial giant cell arteritis with intracranial
involvement.
Methods: In a multicenter retrospective study, we included 31 patients with systemic giant cell arteritis (GCA) with intracra-
nial involvement. Clinical characteristics, pattern of arterial involvement, and cytokine profiles were assessed. Patients with
GCA without intracranial involvement (n = 17), and with intracranial atherosclerosis (n = 25) served as controls.
Results: Erythrocyte sedimentation rate (ESR) was elevated in 18 patients (69.2%) with and in 16 patients (100%) with-
out intracranial involvement (p = 0.02). Headache was complained by 15 patients (50.0%) with and 13 patients (76.5%)
without intracranial involvement (p = 0.03). Posterior circulation arteries were affected in 26 patients (83.9%), anterior
circulation arteries in 17 patients (54.8%), and both territories in 12 patients (38.7%). Patients with GCA had vertebral
artery stenosis proximal and, in contrast, patients with atherosclerosis distal to the origin of posterior inferior cerebellar
artery (PICA). Among patients with GCA with intracranial involvement, 11 patients (37.9%) had a rapid progressive dis-
ease course characterized by short-term recurrent ischemic events. The median modified Rankin Scale (mRS) at follow-
up in these patients was 4 (interquartile range [IQR] = 2.0–6.0) and 4 patients (36.4%) died. Vessel wall expression of
IL-6 and IL-17 was significantly increased in patients with rapid progressive course.
Interpretation: Typical characteristics of GCA, headache, and an elevated ESR, are frequently absent in patients with
intracranial involvement. However, differentiation of intracranial GCA from atherosclerosis can be facilitated by the typ-
ical pattern of vertebral artery stenosis. About one-third of patients with intracranial GCA had a rapid progressive
course with poor outcome. IL-17 and IL-6 may represent potential future treatment targets.
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Giant cell arteritis (GCA) is the most common sys-temic vasculitis.1 It affects mostly people older than
50 years of age.2 Inflammation mainly involves the
medium- and large-sized arteries, especially the proximal
aorta and its branches.3,4 The clinical findings in GCA
commonly include new-onset headache, tenderness of the
scalp, fatigue, fever, jaw claudication, and acute vision
loss.3 High-dose systemic glucocorticoids remain the
mainstay of treatment and should be instituted promptly
once the diagnosis of GCA as the cause of symptoms is
strongly suspected.1 The prevalence of adverse side effects
of long term glucocorticoid therapy is high and patients
with pre-existing comorbidities and a persisting high bur-
den of inflammatory disease benefit from glucocorticoid-
sparing agents, such as methotrexate or tocilizumab.1,5,6
Data on the involvement of intracranial arteries in GCA
are sparse and are reported in approximately 4% of
patients with GCA7–9 with a high potential of cerebrovas-
cular complications.8,10–12 Intracranial arteritic involve-
ment can occur in the distribution of both the internal
carotid and vertebrobasilar arteries, but is conspicuously
more common in the posterior circulation.6–8,13 However,
a comprehensive engram of patients with intracranial
involvement is lacking so far. Furthermore, pathophysio-
logical differences between patients with and without
intracranial involvement are unknown.
The aim of the present study was to characterize
clinical, imaging, laboratory, and histological features of
patients with GCA with intracranial involvement.
Methods
Standard Protocol Approvals, Registrations, and
Patient Consents
Written informed consent for usage of biopsy samples and
clinical data was obtained in all patients. The study was
conducted according to the declaration of Helsinki and
approved by the local ethics committee of all participating
centers (AZ 2018-623-f-S).
Study Oversight
We conducted a multicenter retrospective study in a
cohort of patients with GCA with intracranial involve-
ment from 5 different neurology departments. We
included patients with the diagnosis of GCA who met the
American College of Rheumatology (ACR) classification
criteria for GCA.14 The GCA diagnosis in patients with
intracranial involvement was confirmed by temporal artery
biopsy in 18 and by means of imaging in 13 patients.
Accordingly, all patients included in our study had an
additional extracranial disease manifestation. Therefore,
these patients must be distinguished from the previously
described disease entity of “Granulomatous Angiitis of the
Central Nervous System.”15 This clinicopathologic entity
differs from GCA with intracranial involvement analyzed
in our cohort, because in the former small intracranial
arteries are affected. We included the following control
groups and subgroups for the identification and descrip-
tion of typical characteristics in intracranial GCA: to
determine specific differences in clinical baseline character-
istics we first compared patients with GCA with intracra-
nial involvement (n = 31) to patients with classical GCA
without intracranial involvement (n = 17). We next sepa-
rated patients with GCA with intracranial involvement in
patients with (n = 11) and without (n = 20) a rapid pro-
gressive disease course to delineate differences in treatment
response and outcome among these subtypes. To differen-
tiate patients with GCA with intracranial involvement
from patients with atherosclerosis, the relevant differential
diagnosis, we compared the pattern of vertebral artery
affection in these 2 groups. At least, flow cytometric cere-
brospinal fluid (CSF) immune cell characteristics of
patients with intracranial GCA were compared to a group
of 12 age-matched patients retrospectively diagnosed with
somatoform disorders without any signs of inflammatory
CSF symptoms.
Patients
We included patients admitted to the Departments of
Neurology at the University Hospital Münster, the
Asklepios Klinik Hamburg Altona, the HELIOS Hospital
Uelzen, the University Hospital Hamburg-Eppendorf, and
the University Hospital Bern. Data collection included
(1) demographics; (2) laboratory investigations (CSF and
blood); (3) imaging results (computed tomography
[CT] imaging, magnetic resonance [MR] imaging, and
conventional angiogram findings); (4) disease characteris-
tics (presenting symptoms and disease course); (5) histopa-
thology of biopsy specimen; (6) treatment course; and
(7) outcome.
Using Adobe Illustrator (Adobe Ilustrator CS5),
HeatMaps of involved artery segments were drawn from
imaging findings (CT or MR angiography or cerebral
angiography) of 21 patients with GCA with intracranial
involvement and were compared to 25 patients with ath-
erosclerotic disease (7 women and 18 men;
mean = 76 years, range = 53–95 years). Disability at
follow-up was assessed by the modified Rankin scale
(mRS).16
Immunohistochemical Analysis of GCA Biopsy
Samples
Immunohistochemistry was performed on tissue samples
from arteries of patients with GCA and intracranial
involvement (n = 6) and compared to patients with GCA
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without involvement of intracranial arteries (n = 6). Tem-
poral artery samples from 3 healthy patients without GCA
served as reference. Paraffin-embedded sections from the
tonsils and appendix were used as positive controls for
cytokine staining. Human artery and control sections were
rehydrated and antigens unmasked (EnVisionTM FLEX
Target Retrieval Solution, pH 9.0) under heat. After
washing (phosphate-buffered saline [PBS], 0.02% Tween
20), sections were incubated in PBS (10% fetal bovine
serum [FBS], 20 minutes) and stained using the following
primary antibodies (4C overnight): CD3 (1:20, mouse
anti-human; Biolegend), CD68 (1:10, mouse anti-human;
Biolegend), IL-1 (1:250, rabbit anti-human; Abcam), IL-6
(1:250, rabbit anti-human; Abcam), IL-12 (1:250, goat
anti-human; Abcam), IL-17 (1:250, rabbit anti-human;
Abcam), IL-23 (1:250, rabbit anti-human; Abcam), and
TNFα (1:150, mouse anti-human; Abcam). After washing
in PBS (3 times for 10 minutes), we used a biotinylated
goat anti-mouse (1:100; Jackson), donkey anti-goat
(1:100; Abcam), or a donkey anti-rabbit (1:100; Abcam)
antibody for detection of primary antibodies. Subse-
quently, slides were washed again (PBS, 3 times
10 minutes) and sections were stained with Streptavidin
AF488 (1:100; Life Technologies Ltd.). In case of double
stainings, epitopes were detected with primary antibodies
accordingly. Cell-specific markers (CD3 and CD68) were
labeled directly using secondary goat anti-mouse594 anti-
body (1:100; Life Technologies Ltd.). All stainings were
mounted with Vectashield Mounting Medium with DAPI
(Vector). Images were taken with a Nikon Eclipse 80i
fluorescence microscope (Nikon) and a Zeiss AxioVision
Apotome (Carl Zeiss). High-definition photographs of
fluorescence-stained vessels for densitometric analyses were
taken with a Keyence BZ-9000 (Biorevo). ImageJ software
version 1.48 was used for densitometric quantification.
Cytokine signal intensities were measured using a modi-
fied densitometric analysis technique described else-
where.17 Briefly, whole vessel images (8 bit) underwent
2 processing steps using ImageJ: background noise was
reduced with a 20 pixels wide rolling-ball subtraction
followed by median filter (2 pixels wide). Remaining
pixels between gray values 11 to 100 were considered
cytokine-positive and summed for each vessel. Signal
intensity of control vessel tissue was set as reference
(100%). Cytokine expression was analyzed separately
within intima, media, and adventitia. Final values were
expressed as relative expression between patients and
controls.
Specimen Handling and Routine CSF Evaluation
Patients with rapid progressive GCA were compared to a
group of 12 age-matched patients retrospectively
diagnosed with somatoform disorders without any signs of
inflammatory CSF conditions (ie, <5 cells/μl CSF,
<2 mmol/l lactate, no blood/CSF-barrier disruption, no
intrathecal immunoglobulin synthesis [Reiber/OCB]).
CSF samples were analyzed within 1 hour after lumbar
puncture by centrifugation at 290 g for 15 minutes at
4C in parallel with 100 μl peripheral blood. Blood-tinged
CSF samples were excluded from the study. After treat-
ment with VersaLyse buffer (Beckman Coulter) for
10 minutes, the samples were washed twice by addition of
3 ml FC-buffer (PBS [Sigma] supplemented with 2%
heat-inactivated FCS Gold [BioSell] and 2 mM EDTA
[Sigma]) and subsequent centrifugation at 290 g for
4 minutes. Following staining with CD14-FITC,
CD3-PC5.5, CD56-PC7, CD4-APC, CD19-APC-
AF700, CD8-PacificBlue, and CD45-KromeOrange (all
Beckman Coulter), samples were washed once with FC
buffer. After aspirating the supernatant, samples were re-
suspended and 20 μl flow count fluorospheres (Beckman
Coulter) were added prior to acquisition using a Navios
flow cytometer (Beckman Coulter). Resulting files were
analyzed by Kaluza 2.1 (Beckman Coulter).
Statistical Analysis
Categorical variables are expressed as numbers (%), and
quantitative variables are expressed as medians (inter-
quartile range [IQR]). Statistical analysis was performed
using GraphPad Prism version 8 (GraphPad Software, La
Jolla, CA). Data were checked for normal distribution
applying the Shapiro–Wilk normality test followed by
group comparison using the Student’s t test or Mann–
Whitney U test. Patient groups were compared by use of
Pearson chi-square test for categorical variables and Stu-
dent’s t test or Mann–Whitney U test for continuous vari-
ables. A p value of <0.05 was considered significant.
Results
Patient Characteristics
The baseline characteristics of the study population are
shown in Table 1. We included 31 patients with GCA
with and 17 patients with GCA without intracranial
involvement. The median time from symptom onset until
diagnosis of GCA was 2 weeks (IQR = 1–4 weeks) and
did not differ between patients with and without involve-
ment of intracranial arteries (3 weeks [IQR = 1–5] vs
1 week [1–4], respectively; p = 0.57). Demographic char-
acteristics did not differ between these 2 groups. Patients
with intracranial involvement less frequently presented
with headache (50.0% vs 76.5%, p = 0.03) and elevated
erythrocyte sedimentation rate (ESR; 69.2% vs
100%, p = 0.02).
3
Beuker et al: Intracranial Giant Cell Arteritis
Characteristics of Central Nervous System
Involvement
In patients with GCA with intracranial involvement, focal
neurological deficits due to intracranial vasculitis at disease
onset mainly consisted of motor (33.3%), speech
(33.3%), and cerebellar (30.0%) deficits. Table 2 summa-
rizes the central nervous system (CNS) affection in
patients with intracranial involvement.
Of 31 patients with GCA with intracranial involve-
ment, neuroimaging showed ischemic strokes in
25 patients (80.6%), 10 patients (32.3%) had sup-
ratentorial, 21 patients (67.7%) had infratentorial, and
7 patients (22.6%) had both supra- and infratentorial stro-
kes (see Table 2). Fourteen patients (45.2%) had bilateral
ischemic strokes. Twenty-six patients (83.9%) had verte-
bral artery stenosis. Within this group, 15 patients
(57.7%) had bilateral involvement of the vertebral artery,
occlusion occurred in 8 patients (31.0%). Heatmaps
illustrating the pattern of intracranial vertebral artery ste-
nosis are shown in Figure 1. The V3 and V4 segment of
the vertebral artery were most commonly affected (Fig 1A,
B). As vertebral artery changes due to GCA are difficult to
distinguish from atherosclerosis, we systematically com-
pared stenosis pattern in patients with GCA to those with
atherosclerosis (control group). Patients in the control
group were found to have involvement of the V4 segment
of the vertebral artery after the posterior inferior cerebellar
artery (PICA) origin, whereas in patients with GCA, the
V3 segment as well as the V4 segment before the PICA
origin were affected (Fig 1A–D). This difference was sta-
tistically significant (p = 0.03). In addition, in GCA, ste-
noses were rather spreading over a long arterial segment in
line with the “slope sign” known from axillary artery affec-
tion in GCA.18 This pattern stands in marked contrast to
the short-segment stenoses observable in patients with ath-
erosclerosis. Heatmaps of carotid artery involvement
TABLE 1. Baseline Characteristics of GCA Study Population
Patients with GCA with
intracranial involvement
(n = 31)
Patients with GCA without
intracranial involvement
(n = 17) p valuea
Demographics
Age, mean (SD), years 73.6 (7.0) 70.9 (8.2) 0.33
Women, n (%) 21 (67.7) 13 (76.5) 0.74
Comorbidities, n (%)
Hypertension 21/29 (72.4) 10/17 (58.8) 0.52
Diabetes mellitus 9/29 (31.0) 2/17 (11.8) 0.17
Nicotine abuse 6/29 (20.7) 0/17 (0) 0.07
Hyperlipidemia 8/29 (27.6) 6/17 (35.3) 0.74
Atrial fibrillation 2/29 (6.9) 1/17 (5.9) 1.0
GCA symptoms, n (%)
Visual disturbances 19/30 (63.3) 8/17 (47.1) 0.36
Headache 15/30 (50.0) 13/17 (76.5) 0.03
Weight loss 3/30 (10.0) 3/17 (17.6) 1.0
Jaw claudication 8/30 (26.7) 2/17 (11.8) 0.29
STA abnormalities 19/30 (63.3) 7/17 (41.2) 0.22
Laboratory findings, n (%)
Elevated CRP 25/30 (83.3) 13/16 (81.2) 1.0
Elevated ESR 18/26 (69.2) 16/16 (100) 0.02
Elevated CRP and ESR 16/25 (64.0) 13/16 (81.2) 0.31
Clinical (average age, sex, and GCA symptoms) and laboratory characteristics of all patients with GCA with (n = 31) and without (n = 17) intracra-
nial involvement included in the study after screening are depicted. Values are the number (%) or mean (SD).
aThe p value for comparisons of patients in all 2 groups.
CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; GCA = giant cell arteritis; STA = superficial temporal artery.
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showed predominantly bilateral stenosis located within the
carotid siphon (Fig 1E, F).
Cerebrospinal fluid (CSF) examinations were per-
formed in 7 patients (24.1%) with GCA with intracranial
involvement (see Table 2). Abnormal CSF was found in
5 patients (71.4%), including lymphocytic pleocytosis
in 1 patient (14.3%) and an increased total protein in
4 patients (57.1%). Flow cytometry based analysis of CSF
and peripheral blood immune cell subsets of 4 patients
with intracranial involvement GCA were compared to a
group of 12 age-matched patients retrospectively diag-
nosed with somatoform disorders without any signs of
inflammatory CSF symptoms (Fig 2A–H).19 Comparison
of major CSF leukocyte subsets revealed a reduction of
total lymphocyte cell count in the CSF of patients with
GCA (see Fig 2C–E). The number of granulocytes in the
peripheral blood was increased in patients with GCA com-
pared to the control group (see Fig 2A). Overall, propor-
tions of leukocyte subsets, including monocytes, CD4+
and CD8+T cells, CD19+B cells, NK cells, and NKT
cells, did not differ between controls and patients with
GCA, neither in the peripheral blood nor in the CSF.
Clinical Course and Treatment
In our study, 11 patients (37.9%) had a rapid progressive
disease course characterized by recurrent ischemic events
and thus representing a distinct subgroup of patients with
GCA with intracranial involvement. Figure 3 illustrates
the clinical disease course and treatment strategies in these
patients. The median time from symptom onset until first
ischemic stroke was 2 months (range = 1–52 months).
Three patients developed stroke at the same time they
presented with GCA symptoms.
All patients with intracranial involvement received
treatment with oral or intravenous glucocorticoids
(Table 3), 19 patients in combination with an immuno-
suppressant agent (azathioprine, cyclophosphamide, meth-
otrexate, or tocilizumab). Tocilizumab was added to the
regimen for 6 patients with either severe disease course or
insufficient response to initial therapy.
Follow-up was available in 24 patients with a
median of 6 months (IQR = 3.5–49.0) after hospital dis-
charge (see Table 3). In 2 patients, outcome data were
only available at hospital discharge. Patients with rapid
progressive disease course had a higher level of disability
(median mRS 4.0 vs 1.5, p = 0.035) at the last follow-up.
Mortality rate was numerically higher in cases of rapid
progressive disease course (4/11 [36.4%] vs 2/20 [10.0%],
p = 0.15). In 1 patient with rapid progressive disease, per-
cutaneous transluminal angioplasty (PTA)/stenting was
performed as last resort treatment. No complications were
reported and the patient was discharged with partial
TABLE 2. CNS Affection in Patients with Intracranial
Involvement
Patients with intracranial
involvement (n = 31)





Vigilance disturbance 4 (13.3)
NIHSS score, median (IQR)
At onset 2 (0–4)
At disease course 2 (0.5–11.5)
Affected arteries, n (%)
Internal carotid artery 15 (48.4)
Middle cerebral artery 6 (19.4)
Posterior cerebral artery 6 (19.4)
Vertebral artery 26 (83.9)
Basilar artery 5 (16.1)
Carotid and vertebrobasilar 12 (38.7)
Cerebral infarction, n (%)
Carotid territory 10 (32.3)
Cerebellar 18 (58.1)
Brain stem 9 (29.0)
Bilateral infarction 14 (45.2)
Abnormal CSF, n (%) 5/7 (71.4)
Pleocytosis,c n (%) 1/7 (14.3)
Leucocyte count, median (IQR), cells/
mm3
0 (0–2)
Increased protein level,d n (%) 4/7 (57.1)
Protein level, median (IQR), mg/dl 49.9 (39.2–83.8)
Flow cytometry (CSF), n (%)
Lymphocytic profile 3/5
Lympho-monocytic profile 1/5
Mixed cellular profile 1/5
Values are the number (%) or median (IQR). CSF parameters of patients
with GCA with intracranial involvement (n = 31) included in the study
are depicted. CSF samples analyzed by flow cytometry of controls (IIH,
n = 15) compared to patients with intracranial involvement (n = 5).
aAt disease manifestation.
bOf 28 patients.
cGreater than or equal to 5cells/μl.
dGreater than 45 mg/dl.
CSF = cerebrospinal fluid; CNS = central nervous system;
IIH = idiopathic intracranial hypertension; IQR = interquartile
range; NIHSS = National Institutes of Health Stroke Scale.
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FIGURE 1: Imaging findings and HeatMaps of involved arteries. (A) Cerebral angiogram demonstrating short-segment stenosis
(white arrows) of the vertebral artery distal to the PICA origin in a patient with atherosclerosis. (B) Cerebral angiogram
demonstrating multiple distal artery stenoses (white arrows) in a patient with intracranial involvement in GCA. (C) HeatMap with
color legend indicating the location of vertebral artery stenosis was constructed by combining pattern of patients with GCA with
intracranial involvement (n = 21). (D) HeatMap with color legend indicating the location of vertebral artery stenosis in control
patients with atherosclerosis (n = 25). (E) HeatMap with color legend indicating the location of internal carotid artery and medial
cerebral artery stenosis was constructed by combining pattern of patients with intracranial involvement (n = 10). (F) Patient with
bilateral carotid siphon stenosis on MRI-TOF-angiography.
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remission. In patients without rapid progressive disease,
PTA/stenting was performed in only 2 patients leading to
death due to procedural complications in both patients.
However, interpretation and comparison of response to
treatment (immunosuppressive regimen, interventional
treatment, and outcome) is limited by the retrospective
design of the study and the comparably small simple size.
Cytokine Expression Pattern in Patients with
Rapid Progressive Intracranial GCA
Histological samples from temporal artery biopsy from
6 patients with GCA with intracranial involvement and
rapid progressive disease course were compared to
6 patients with GCA without involvement of intracranial
arteries as controls. Tissue was obtained from biopsy sam-
ples, whereas in 2 patients, autopsy tissue was analyzed. In
these cases, postmortem examination of the vertebral arter-
ies was performed in addition to the histological assess-
ment of temporal artery biopsy. Hematoxylin–eosin and
Elastica van Gieson staining of superficial temporal artery
(STA) showed characteristic histopathologic findings
including a panarteritis composed of CD4+ lymphocytes
and macrophages with fragmentation of internal elastic
lamina and a few giant cells in all biopsy specimen
(Fig 4A). In GCA, inflammation typically starts in the
adventitia and spreads to the inner layers of the vessel wall
(media and intima).1 Distinct patterns of arterial
wall involvement were observed when comparing the
expression profiles of cytokines known to be involved in
the pathophysiology of GCA (IL-1, IL-6, IL-12, IL-17,
IL-23, and TNFα)1 among tissue samples (see Fig 4B–G).
The expression profile of IL-1, IL-12, and TNFα was
comparable between patients with and without rapid pro-
gressive disease course (see Fig 4B, F, G). These cytokines
were predominantly detectable in the adventitia and to a
lesser extent in the media in both disease subtypes. In
contrast, IL-17 and IL-23 were mainly expressed in the
media layer in both disease subtypes (see Fig 4C, E).
Notably, we observed an increase of IL-6 in the intimal
and of IL-17 in the medial wall segment in the rapid pro-
gressive subtype in comparison to patients without rapid
progressive disease course indicating an increased inflam-
mation in these patients (see Fig 4C, D). We labeled these
markers together with CD68 (macrophages) and CD3
(T cells). In line with pathogenetic pathways in GCA,20
IL-6 was frequently expressed by CD68+ cells that were
morphologically classified as macrophages (see Fig 4D).
The marker IL-17 was expressed by CD3+ cells (see
FIGURE 2: Leukocyte subsets in GCA. Leukocytes from the peripheral blood (PB) and cerebrospinal fluid (CSF) from four patients
with GCA with intracranial involvement compared to 12 age-matched patients retrospectively diagnosed with somatoform
disorders were stained with fluorochrome-conjugated antibodies and analyzed by flow cytometry. Leukocytes were selected
based on forward scatter channel (FSC) characteristics as CD45 expressing cells and further divided into (A) granulocytes,
(B) monocytes, and (C) lymphocytes by side scatter channel (SSC) versus CD14 characteristics. (D) T cells and (E) CD4 as well as
(F) CD8 T-cell subsets were identified by flow cytometry as CD3+ CD56 lymphocytes expressing CD4 or CD8. (G) B cells were
characterized as CD19+ CD138 lymphocytes. (H) NK cells were identified as CD56+ CD3 lymphocytes. Cell numbers from
controls (blue circle) and patients with GCA (red triangle down) are displayed. Error bars indicate the SEM. Results from different
groups were compared using Mann–Whitney U test; *p < 0.05, **p > 0.01. GCA = giant cell arteritis.
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Fig 4C) indicating TH17 cells that are known to attract
new macrophages via the production of IL-17 as a patho-
genetic mechanism in GCA.21
Discussion
In this multicenter retrospective study, we provide a com-
prehensive characterization of patients with GCA with
intracranial involvement. Our findings extend current
knowledge on this distinct disease subtype. Typical clinical
findings, such as headache and elevated ESR, are fre-
quently absent in these patients. Notably, we identified a
specific vessel pattern in patients with intracranial involve-
ment (ie, stenosis of the V3 and V4 segment of the verte-
bral artery) that might help in distinguishing from
atherosclerotic stenoses by affection prior to the PICA
origin. About one third of patients had a rapid progres-
sive disease course characterized by short-term recurrent
ischemic events, poor neurological outcome, high
mortality, and a specific vessel wall cytokine expression
profile.
So far, there are only a few case reports and case
series on patients with intracranial involvement in GCA.7–9
In 1968, Kolodny et al were one of the first to describe gran-
ulomatous angiitis of the CNS.15 However, in contrast to
our cohort, the patients in their study did not have extracra-
nial involvement. GCA with involvement of intracranial
arteries is difficult to diagnose for several reasons. First, typi-
cal clinical GCA findings, such as headache and elevated
ESR, may be absent in these patients. In previous studies,
elevated ESR rates were reported in virtually all patients with
GCA,2,22,23 whereas our results indicate a relevant number
of normal ESR rates among patients with intracranial
involvement. Second, onset of GCA symptoms and stroke
frequently occur simultaneously. A third reason is that the
distinction from atherosclerosis is difficult, because cerebro-
vascular risk factors that might in turn cause atherosclerotic
disease, are often found in patients with intracranial GCA.
FIGURE 3: Disease course and immune therapies of patients with rapid progressive GCA. Shown are timeline data of 11 patients
with GCA with intracranial involvement and rapid progressive disease course. Included are clinical episodes, NIHSS, treatments,
time of intubation, and death. Black cross indicates death; blue diamond indicates ischemic stroke; brown line indicates
tocilizumab; D = days; empty blue diamond indicates transient ischemic attack (TIA); GCS indicates glucocorticoids; green line
indicates oral glucocorticoids; grey block indicates high-dose MTX; orange block indicates intubation; red line indicates iv
cyclophosphamide; and turquoise line indicates iv pulses of glucocorticoids. GCA = giant cell arteritis; GCS = glucosylceramide
synthase; Mo = months; MTX = methotrexate; N/A = not applicable; NIHSS = National Institutes of Health Stroke Scale.
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Moreover, our results show that, in comparison to other vas-
culitides of the CNS,24 intracranial arteritis in GCA was not
reflected by changes in CSF immune cell composition. How-
ever, immunosuppressive therapy in these patients (glucocor-
ticoids and/or cyclophosphamide) was initiated before CSF
analysis and might have contributed to this observation.
Consequently, the pattern of vertebral artery involvement
affecting the V3 and V4 segment before the origin of the
PICA may be helpful in establishing the diagnosis correctly.
Glucocorticoids and immunosuppressive agents,
such as methotrexate and tocilizumab, are currently the
standard for treating GCA. However, we observed a poor
response rate in patients with rapid progressive disease
course to these established therapy regimens. Several case
reports suggest that cyclophosphamide has been success-
fully used in GCA with intracranial involvement.9,10,25
Remarkably, in our series, early initiation and combina-
tion with cyclophosphamide (in 3 cases) did not prevent
the patients from recurrent stroke and poor outcome.
Thus, very early implementation of sufficient immunosup-
pressant therapy (other than cyclophosphamide) might
increase possible beneficial outcomes. We therefore ana-
lyzed biopsy samples from patients with intracranial
involvement in order to determine new treatment targets.
Histologically, we found IL-6 and IL-17, both known to
be involved in the pathogenesis of GCA,20 highly
TABLE 3. Treatment and Outcome of Patients with Intracranial Involvement
All patients with GCA with
intracranial
involvement (n = 31)
Patients with GCA with
intracranial involvement
with rapid progressive
course (n = 11)
Patients with GCA with
intracranial involvement
without rapid progressive
course (n = 20)
Treatment, n (%)
GC alone 11 (35.5) 5 (45.4) 6 (30.0)
GC and CYC 6 (19.4) 2 (18.2) 4 (20.0)
GC and AZA 1 (3.2) 0 (0) 1 (5.0)
GC and MTX 2 (6.5) 0 (0) 2 (10.0)
GC and tocilizumab 4 (12.9) 1 (9.1) 3 (15.0)
GC, CYC, and
tocilizumab
3 (9.7) 2 (18.2) 1 (5.0)




8.5 (3.5–49.0) 5.5 (3.5–9.8) 19.5 (4.8–62.3)
Death, n (%) 6 (19.4) 4 (36.4) 2a (11.8)
mRS
At last follow-up, median
(IQR)
2.1 (1.0–4.5) 4 (2.0–6.0) 1.5 (1.0–2.8)
0–2, n (%) 17 (54.8) 4 (36.4) 14 (70.0)
3–4, n (%) 5 (16.1) 2 (18.2) 3 (15.0)
5–6, n (%) 8 (25.8) 5 (45.4) 3 (15.0)
Treatment and outcome information of patients with GCA with intracranial involvement (n = 31) included in the study after screening are depicted.
These patients were divided into 2 subgroup cohorts, cohort 1 = patients with rapid progressive disease course (n = 11) and cohort 2 = patients with-
out rapid progressive disease course (n = 20). Values are the number (%) or median (IQR).
aDue to complication from intervention.
AZA = azathioprine; CYC = cyclophosphamide; GC = glucocorticoids; GCA = giant cell arteritis; IQR = interquartile range; mRS = modified
Rankin Scale; MTX = methotrexate.
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FIGURE 4: Cytokine expression pattern in patients with GCA. (A) Representative H&E and EvG-staining of TBA sample with transmural
inflammation, intimal thickening, luminal stenosis, giant cells, and fragmentation of internal elastic lamina. (B–G) Cytokine expression was
quantified within the intimal, medial, and adventitial layer of the vessel wall. Patients were divided in 2 groups, group 1 = patients with
GCA without intracranial involvement (n = 6) and group 2 = patients with GCA with intracranial involvement and rapid progressive
disease course (n = 6). Data of control patients (n = 3) are shown with dotted lines. Data are presented as mean  SEM (t test,
*p < 0.05). TBA samples were stained with IL-1, IL-17, IL-6, IL-23, IL-12, or TNFα. Scale bars represent 25, 50, or 100 μm (as indicated).
(B–D) Samples were co-stained for IL-1 or IL-6 together with CD68, and IL-17 together with CD3 indicating the cellular source of
cytokine production. GCA = giant cell arteritis; H&E = hematoxylin and eosin stain; TBA = total bile acid.
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expressed in the vessel wall of biopsy samples from
patients with intracranial involvement. Strong evidence
suggests that IL-6 inhibition with tocilizumab plays a
major role in suppressing disease activity in GCA and,
recently, tocilizumab in combination with prednisone was
superior to prednisone alone.5,26,27 In our cohort,
2 patients experienced relapsing disease with recurrent
ischemic events despite treatment with tocilizumab (initia-
tion: iv n = 1, sc n = 1), whereas in 2 other patients sta-
ble, remission had been achieved. The efficacy and safety
of IL-17A inhibitors (eg, secukinumab) is currently being
tested in clinical trials. In conclusion, early administration
of IL-6 or IL-17A receptor blocker in patients with intra-
cranial GCA should be the subject of future research.
In our cohort, 2 patients with multiple intracranial
stenosis within the vertebrobasilar and the carotid vascular
territory died from complications of endovascular treat-
ment. In contrast, previous studies report successful endo-
vascular treatment in patients with progressive intracranial
stenosis in GCA.28–32 However, reports of endovascular
intervention with favorable results are more likely to be
published than failed attempts. On the other side, these
data must be judged considering the retrospective study
design. Thus, it is possible, that balloon dilatation and/or
stenting of edematous and inflamed vessels harbors a high
risk of rupture and re-occlusion and should be considered
a rescue therapy in patients with progressive strokes.
Our study has limitations due to its retrospective
design; given that comparisons of differences in evaluation
and treatment are difficult and control data are limited.
Therefore, conclusions about superiority of different treat-
ments cannot be drawn from our study. Furthermore, the
interpretation is limited by the comparably small size.
The latter, though, is a result of the rareness of this spe-
cific disease subtype. Additionally, the high number of
strokes in our cohort may be confounded by the fact that
only patients with GCA from neurology departments were
included. A strength of our study is the comprehensive
and multimodal characterization, which includes compari-
son with patients with atherosclerotic disease, GCA with-
out intracranial involvement, and healthy controls.
Moreover, our study has high clinical implication as it
identifies a distinct disease subtype and provides evidence
for different pathophysiological mechanisms among the
latter.
In summary, we describe patients with GCA with
intracranial involvement and its subtype with progressive
disease course. Above that, our study identifies a specific
pattern of vertebral artery affection, which helps
distinguishing GCA from stenosis due to atherosclerosis
(ie, vertebral artery stenosis proximal versus distal to the
origin of the PICA). Enhanced knowledge of the
pathophysiology of distinct disease subtypes in GCA will
help to identify therapeutic targets to halt or even reverse
disease progression in severe cases.
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